Cathelicidins Have Direct Antiviral Activity against Respiratory Syncytial Virus In Vitro and Protective Function In Vivo in Mice and Humans
Silke M Currie, Emily Gwyer Findlay, Amanda J McFarlane, Paul M Fitch, Bettina Böttcher, Nick Colegrave, Allan Paras, Agnieszka Jozwik, Christopher Chiu, Jürgen Schwarze, Donald J Davidson, Silke M Currie, Emily Gwyer Findlay, Amanda J McFarlane, Paul M Fitch, Bettina Böttcher, Nick Colegrave, Allan Paras, Agnieszka Jozwik, Christopher Chiu, Jürgen Schwarze, Donald J Davidson
Abstract
Respiratory syncytial virus (RSV) is a leading cause of respiratory tract infection in infants, causing significant morbidity and mortality. No vaccine or specific, effective treatment is currently available. A more complete understanding of the key components of effective host response to RSV and novel preventative and therapeutic interventions are urgently required. Cathelicidins are host defense peptides, expressed in the inflamed lung, with key microbicidal and modulatory roles in innate host defense against infection. In this article, we demonstrate that the human cathelicidin LL-37 mediates an antiviral effect on RSV by inducing direct damage to the viral envelope, disrupting viral particles and decreasing virus binding to, and infection of, human epithelial cells in vitro. In addition, exogenously applied LL-37 is protective against RSV-mediated disease in vivo, in a murine model of pulmonary RSV infection, demonstrating maximal efficacy when applied concomitantly with virus. Furthermore, endogenous murine cathelicidin, induced by infection, has a fundamental role in protection against disease in vivo postinfection with RSV. Finally, higher nasal levels of LL-37 are associated with protection in a healthy human adult RSV infection model. These data lead us to propose that cathelicidins are a key, nonredundant component of host defense against pulmonary infection with RSV, functioning as a first point of contact antiviral shield and having additional later-phase roles in minimizing the severity of disease outcome. Consequently, cathelicidins represent an inducible target for preventative strategies against RSV infection and may inform the design of novel therapeutic analogs for use in established infection.
Copyright © 2016 The Authors.
Figures
References
- Borchers A. T., Chang C., Gershwin M. E., Gershwin L. J. 2013. Respiratory syncytial virus--a comprehensive review. Clin. Rev. Allergy Immunol. 45: 331–379.
- Smyth R. L., Openshaw P. J. 2006. Bronchiolitis. Lancet 368: 312–322.
- Nair H., Nokes D. J., Gessner B. D., Dherani M., Madhi S. A., Singleton R. J., O’Brien K. L., Roca A., Wright P. F., Bruce N., et al. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375: 1545–1555.
- Krishnamoorthy N., Khare A., Oriss T. B., Raundhal M., Morse C., Yarlagadda M., Wenzel S. E., Moore M. L., Peebles R. S., Jr., Ray A., Ray P. 2012. Early infection with respiratory syncytial virus impairs regulatory T cell function and increases susceptibility to allergic asthma. Nat. Med. 18: 1525–1530.
- Sigurs N., Aljassim F., Kjellman B., Robinson P. D., Sigurbergsson F., Bjarnason R., Gustafsson P. M. 2010. Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax 65: 1045–1052.
- Tregoning J. S., Schwarze J. 2010. Respiratory viral infections in infants: causes, clinical symptoms, virology, and immunology. Clin. Microbiol. Rev. 23: 74–98.
- Currie S. M., Findlay E. G., McHugh B. J., Mackellar A., Man T., Macmillan D., Wang H., Fitch P. M., Schwarze J., Davidson D. J. 2013. The human cathelicidin LL-37 has antiviral activity against respiratory syncytial virus. PLoS One 8: e73659.
- Beaumont, P. E., H. Li, and D. J. Davidson. 2013. LL-37: an immunomodulatory antimicrobial host defence peptide. In Antimicrobial Peptides and Innate Immunity. P. S. Hiemstra, and S. A. J. Zaat, eds. Springer, Basel, Switzerland, p. 97–122.
- Lai Y., Gallo R. L. 2009. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol. 30: 131–141.
- Bowdish D. M. E., Davidson D. J., Hancock R. E. W. 2006. Immunomodulatory properties of defensins and cathelicidins. Curr. Top. Microbiol. Immunol. 306: 27–66.
- Larrick J. W., Hirata M., Balint R. F., Lee J., Zhong J., Wright S. C. 1995. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect. Immun. 63: 1291–1297.
- Agerberth B., Gunne H., Odeberg J., Kogner P., Boman H. G., Gudmundsson G. H. 1995. FALL-39, a putative human peptide antibiotic, is cysteine-free and expressed in bone marrow and testis. Proc. Natl. Acad. Sci. USA 92: 195–199.
- Gallo R. L., Kim K. J., Bernfield M., Kozak C. A., Zanetti M., Merluzzi L., Gennaro R. 1997. Identification of CRAMP, a cathelin-related antimicrobial peptide expressed in the embryonic and adult mouse. J. Biol. Chem. 272: 13088–13093.
- Sørensen O. E., Follin P., Johnsen A. H., Calafat J., Tjabringa G. S., Hiemstra P. S., Borregaard N. 2001. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood 97: 3951–3959.
- Scott M. G., Davidson D. J., Gold M. R., Bowdish D., Hancock R. E. W. 2002. The human antimicrobial peptide LL-37 is a multifunctional modulator of innate immune responses. J. Immunol. 169: 3883–3891.
- Krzyzaniak M. A., Zumstein M. T., Gerez J. A., Picotti P., Helenius A. 2013. Host cell entry of respiratory syncytial virus involves macropinocytosis followed by proteolytic activation of the F protein. PLoS Pathog. 9: e1003309.
- Nizet V., Ohtake T., Lauth X., Trowbridge J., Rudisill J., Dorschner R. A., Pestonjamasp V., Piraino J., Huttner K., Gallo R. L. 2001. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature 414: 454–457.
- Habibi M. S., Jozwik A., Makris S., Dunning J., Paras A., DeVincenzo J. P., de Haan C. A., Wrammert J., Openshaw P. J., Chiu C. 2015. Impaired antibody-mediated protection and defective IgA B-cell memory in experimental infection of adults with respiratory syncytial virus. Am. J. Respir. Crit. Care Med. 191: 1040–1049.
- Kota S., Sabbah A., Chang T. H., Harnack R., Xiang Y., Meng X., Bose S. 2008. Role of human beta-defensin-2 during tumor necrosis factor-alpha/NF-kappaB-mediated innate antiviral response against human respiratory syncytial virus. J. Biol. Chem. 283: 22417–22429.
- Lepault J., Booy F. P., Dubochet J. 1983. Electron microscopy of frozen biological suspensions. J. Microsc. 129: 89–102.
- Liljeroos L., Krzyzaniak M. A., Helenius A., Butcher S. J. 2013. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc. Natl. Acad. Sci. USA 110: 11133–11138.
- Srinivasakumar N., Ogra P. L., Flanagan T. D. 1991. Characteristics of fusion of respiratory syncytial virus with HEp-2 cells as measured by R18 fluorescence dequenching assay. J. Virol. 65: 4063–4069.
- Prince G. A., Horswood R. L., Berndt J., Suffin S. C., Chanock R. M. 1979. Respiratory syncytial virus infection in inbred mice. Infect. Immun. 26: 764–766.
- Stokes K. L., Chi M. H., Sakamoto K., Newcomb D. C., Currier M. G., Huckabee M. M., Lee S., Goleniewska K., Pretto C., Williams J. V., et al. 2011. Differential pathogenesis of respiratory syncytial virus clinical isolates in BALB/c mice. J. Virol. 85: 5782–5793.
- Openshaw P. J., Tregoning J. S. 2005. Immune responses and disease enhancement during respiratory syncytial virus infection. Clin. Microbiol. Rev. 18: 541–555.
- Hall C. B., Weinberg G. A., Iwane M. K., Blumkin A. K., Edwards K. M., Staat M. A., Auinger P., Griffin M. R., Poehling K. A., Erdman D., et al. 2009. The burden of respiratory syncytial virus infection in young children. N. Engl. J. Med. 360: 588–598.
- Dowell S. F., Anderson L. J., Gary H. E., Jr., Erdman D. D., Plouffe J. F., File T. M., Jr., Marston B. J., Breiman R. F. 1996. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J. Infect. Dis. 174: 456–462.
- Whimbey E., Ghosh S. 2000. Respiratory syncytial virus infections in immunocompromised adults. Curr. Clin. Top. Infect. Dis. 20: 232–255.
- Falsey A. R., Hennessey P. A., Formica M. A., Cox C., Walsh E. E. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352: 1749–1759.
- Glezen W. P., Taber L. H., Frank A. L., Kasel J. A. 1986. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140: 543–546.
- Thomas G. 2015. A cost-benefit analysis of the immunisation of children against respiratory syncytial virus (RSV) using the English Hospital Episode Statistics (HES) data set. Eur. J. Health Econ. .
- Henderson J., Hilliard T. N., Sherriff A., Stalker D., Al Shammari N., Thomas H. M. 2005. Hospitalization for RSV bronchiolitis before 12 months of age and subsequent asthma, atopy and wheeze: a longitudinal birth cohort study. Pediatr. Allergy Immunol. 16: 386–392.
- Bals R., Weiner D. J., Moscioni A. D., Meegalla R. L., Wilson J. M. 1999. Augmentation of innate host defense by expression of a cathelicidin antimicrobial peptide. Infect. Immun. 67: 6084–6089.
- Beaumont P. E., McHugh B., Gwyer Findlay E., Mackellar A., Mackenzie K. J., Gallo R. L., Govan J. R., Simpson A. J., Davidson D. J. 2014. Cathelicidin host defence peptide augments clearance of pulmonary Pseudomonas aeruginosa infection by its influence on neutrophil function in vivo. PLoS One 9: e99029.
- Iimura M., Gallo R. L., Hase K., Miyamoto Y., Eckmann L., Kagnoff M. F. 2005. Cathelicidin mediates innate intestinal defense against colonization with epithelial adherent bacterial pathogens. J. Immunol. 174: 4901–4907.
- Chromek M., Slamová Z., Bergman P., Kovács L., Podracká L., Ehrén I., Hökfelt T., Gudmundsson G. H., Gallo R. L., Agerberth B., Brauner A. 2006. The antimicrobial peptide cathelicidin protects the urinary tract against invasive bacterial infection. Nat. Med. 12: 636–641.
- Huang L. C., Reins R. Y., Gallo R. L., McDermott A. M. 2007. Cathelicidin-deficient (Cnlp -/- ) mice show increased susceptibility to Pseudomonas aeruginosa keratitis. Invest. Ophthalmol. Vis. Sci. 48: 4498–4508.
- Kovach M. A., Ballinger M. N., Newstead M. W., Zeng X., Bhan U., Yu F. S., Moore B. B., Gallo R. L., Standiford T. J. 2012. Cathelicidin-related antimicrobial peptide is required for effective lung mucosal immunity in Gram-negative bacterial pneumonia. J. Immunol. 189: 304–311.
- Gwyer Findlay E., Currie S. M., Davidson D. J. 2013. Cationic host defence peptides: potential as antiviral therapeutics. BioDrugs 27: 479–493.
- Barlow P. G., Svoboda P., Mackellar A., Nash A. A., York I. A., Pohl J., Davidson D. J., Donis R. O. 2011. Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS One 6: e25333.
- Tripathi S., Tecle T., Verma A., Crouch E., White M., Hartshorn K. L. 2013. The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins. J. Gen. Virol. 94: 40–49.
- Lai Y., Adhikarakunnathu S., Bhardwaj K., Ranjith-Kumar C. T., Wen Y., Jordan J. L., Wu L. H., Dragnea B., San Mateo L., Kao C. C. 2011. LL37 and cationic peptides enhance TLR3 signaling by viral double-stranded RNAs. PLoS One 6: e26632.
- Takiguchi T., Morizane S., Yamamoto T., Kajita A., Ikeda K., Iwatsuki K. 2014. Cathelicidin antimicrobial peptide LL-37 augments interferon-β expression and antiviral activity induced by double-stranded RNA in keratinocytes. Br. J. Dermatol. 171: 492–498.
- Liu P., Jamaluddin M., Li K., Garofalo R. P., Casola A., Brasier A. R. 2007. Retinoic acid-inducible gene I mediates early antiviral response and Toll-like receptor 3 expression in respiratory syncytial virus-infected airway epithelial cells. J. Virol. 81: 1401–1411.
- Goritzka M., Makris S., Kausar F., Durant L. R., Pereira C., Kumagai Y., Culley F. J., Mack M., Akira S., Johansson C. 2015. Alveolar macrophage-derived type I interferons orchestrate innate immunity to RSV through recruitment of antiviral monocytes. J. Exp. Med. 212: 699–714.
- Lau Y. E., Rozek A., Scott M. G., Goosney D. L., Davidson D. J., Hancock R. E. 2005. Interaction and cellular localization of the human host defense peptide LL-37 with lung epithelial cells. Infect. Immun. 73: 583–591.
- Dean R. E., O’Brien L. M., Thwaite J. E., Fox M. A., Atkins H., Ulaeto D. O. 2010. A carpet-based mechanism for direct antimicrobial peptide activity against vaccinia virus membranes. Peptides 31: 1966–1972.
- Howell M. D., Jones J. F., Kisich K. O., Streib J. E., Gallo R. L., Leung D. Y. 2004. Selective killing of vaccinia virus by LL-37: implications for eczema vaccinatum. J. Immunol. 172: 1763–1767.
- Hansdottir S., Monick M. M., Hinde S. L., Lovan N., Look D. C., Hunninghake G. W. 2008. Respiratory epithelial cells convert inactive vitamin D to its active form: potential effects on host defense. J. Immunol. 181: 7090–7099.
- Ryan L. K., Dai J., Yin Z., Megjugorac N., Uhlhorn V., Yim S., Schwartz K. D., Abrahams J. M., Diamond G., Fitzgerald-Bocarsly P. 2011. Modulation of human beta-defensin-1 (hBD-1) in plasmacytoid dendritic cells (PDC), monocytes, and epithelial cells by influenza virus, Herpes simplex virus, and Sendai virus and its possible role in innate immunity. J. Leukoc. Biol. 90: 343–356.
- Wang T. T., Nestel F. P., Bourdeau V., Nagai Y., Wang Q., Liao J., Tavera-Mendoza L., Lin R., Hanrahan J. W., Mader S., White J. H. 2004. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol. 173: 2909–2912.
- Sabetta J. R., DePetrillo P., Cipriani R. J., Smardin J., Burns L. A., Landry M. L. 2010. Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. PLoS One 5: e11088.
- Berry D. J., Hesketh K., Power C., Hyppönen E. 2011. Vitamin D status has a linear association with seasonal infections and lung function in British adults. Br. J. Nutr. 106: 1433–1440.
- Belderbos, M. E., M. L. Houben, B. Wilbrink, E. Lentjes, E. M. Bloemen, J. L. Kimpen, M. Rovers, and L. Bont. 2011. Cord blood vitamin D deficiency is associated with respiratory syncytial virus bronchiolitis. Pediatrics 127: e1513–e1520. doi:10.1542/peds.2010-3054.
- Mansbach J. M., Piedra P. A., Borregaard N., Martineau A. R., Neuman M. I., Espinola J. A., Camargo C. A., Jr. 2012. Serum cathelicidin level is associated with viral etiology and severity of bronchiolitis. J. Allergy Clin. Immunol. 130: 1007–1008.e1.
- Al-Mamun A., Mily A., Sarker P., Tiash S., Navarro A., Akter M., Talukder K. A., Islam M. F., Agerberth B., Gudmundsson G. H., et al. 2013. Treatment with phenylbutyrate in a pre-clinical trial reduces diarrhea due to enteropathogenic Escherichia coli: link to cathelicidin induction. Microbes Infect. 15: 939–950.
- Sarker P., Ahmed S., Tiash S., Rekha R. S., Stromberg R., Andersson J., Bergman P., Gudmundsson G. H., Agerberth B., Raqib R. 2011. Phenylbutyrate counteracts Shigella mediated downregulation of cathelicidin in rabbit lung and intestinal epithelia: a potential therapeutic strategy. PLoS One 6: e20637.
- van der Does A. M., Bergman P., Agerberth B., Lindbom L. 2012. Induction of the human cathelicidin LL-37 as a novel treatment against bacterial infections. J. Leukoc. Biol. 92: 735–742.
Source: PubMed